Objectives:
Introduction
Gene transfer vectors derived from adenovirus have proven to be extremely effective for expression of heterologous genes [l] . Their advantages include a broad host range, the ability to obtain high transduction efficiencies in non-replicating cells and the ease of preparation of pure, high-titer stocks. These properties make adenoviral vectors suitable for gene therapy applications, especially for local gene delivery in the cardiovascular system [2-41. Recom-variety of cell types by cytokine stimulation. It contains a tightly bound calmodulin subunit and remains active even at resting levels of intracellular calcium. All three isoenzymes catalyze the five-electron oxidation of L-arginine to L-citrulline. The oxidation requires exogenous NADPH, which binds to the enzyme, transfers electrons through the flavins FAD and FMN, to a heme group and thence to L-arginine. Tetrahydrobiopterin (BH4) maintains the enzyme in its active homodimeric form, and is essential for activity [14, 15] .
Nitric oxide (NO) regulates a broad range of biologic functions [ 161 including vascular tone [ 17,181, neurotransmission, immuno-regulation, and microbial killing. In the cardiovascular system, loss of endothelial NO production is an early event in atherosclerosis and other forms of vascular injury [19] . Early deficiency of endothelial NO production may in turn promote progression to more advanced vascular lesions since NO is an inhibitor of key processes in the pathogenesis of atherosclerosis, including platelet aggregation [20, 21] , leukocyte adhesion and smooth muscle cell proliferation [22, 23] . Since NO plays a key role in the pathogenesis of vascular diseases, the nitric oxide synthases represent attractive targets for vascular gene transfer. The biologic utility of restoring eNOS activity in injured rat carotid arteries was demonstrated using plasmid-liposome gene transfer [24] . An adenoviral vector enabling higher-efficiency gene transfer of NOS would likely have wider therapeutic utility, both in vascular injury states where the endothelium is dysfunctional or lost, and in other organ systems. Accordingly, we aimed to develop an adenoviral vector for gene transfer of NOS.
We have recently developed a novel adenoviral vector system, based on the in340 strain of adenovirus type 5. It has El and E3 deletions, resulting in a cloning capacity of 7.5 kb, more than sufficient to accommodate the nitric oxide synthase cDNAs. In this report, we describe the use of this system to generate a recombinant adenoviral vector for gene transfer of the neuronal-type isoform of nitric oxide synthase (nN0.S). We demonstrate both high level protein expression and functional nNOS enzyme activity in a variety of cell types, highlighting the potential utility of this novel vector for gene transfer and gene therapy applications.
Methods

Construction of recombinant Ad.nNOS
To generate Ad.nNOS we used a novel adenoviral vector system derived from the in340 mutant strain of adenovirus type 5 (Ad5) [25, 26] . The in340 strain is distinguished by a duplicate Ela enhancer/viral packaging signal (Ad5 base pairs (bp) 194-351) at the right (3') end of the virus. To enhance the utility of the in340 strain as a gene transfer vector, we deleted 2749 bp (Ad5 bp 28725-31000) from the E3 region, inserted a nuclear localizing pgalactosidase expression cassette in the El cloning region, and added three unique restriction sites (&I, XbaI and PacI) at the 3' end of the El cloning site (Ad5 bp 3334 Fig. 1 . Construction of recombinant Ad.nNOS. Ad.nNOS was generated by direct ligation of a plasmid fragment containing a nNOS cDNA to a viral 'backbone' derived from the parent vector, Ad.Pac p Gal. The nNOS cDii A was cloned into pGEM CMV, a plasmid designed for generation of viral recombinants by either by ligation or by overlap recombination. pGEM CMV contains the adenovirus 5 (Ad5) inverted terminal repeat (Ad5 bp I-194, 'ITR'), a CMV early enhancer/promoter ('CMV'), a cloning site for the insertion of a heterologous gene, and a portion of ;adenoviraJ DNA for overlap recombination (Ad5 bp 3335-5793). These fragments are located between the EcoRI and XhoI sites of the pGEM 4 plasmid ('pGEM 4'). The nNOS cDNA was cloned into the BarnHI-Xbal sites of pGEM CMV, generating the plasmid pGEM CMV nNOS. This plasmid was modified by removing the 3' non-coding region of the nNOS cDNA by digestion with Not1 and Xbal, and replacing it with an SV40 VP2 polyadenylation signal ('PA'), generating pGEM CMV nNOS pA. This plasmid was restriction digested with CIaI and Klenow DNA polymerase was used to create a blunt end. A 6 kb fragment, containing the left Ad5 ITR, CMV promoter, nNOS cDNA and SV40 pA, was generated by digestion of the linearized, blunted plasmid with XbaI. The DNA 'backbone' of the vector was prepared by XbaI digestion of genomic DNA from the parent vector, Ad.Pac p Gal, generating a 27 kb fragment with an ITR and the viral packaging signal ('PKG') at the extreme 5' end. Both the 6 kb plasmid fragment and the 27 kb viral fragment were isolated from low-melt agarose gels by P-agarase digestion and ethanol precipitation. These fragments were ligated for 1 hour at room temperature using T4 DNA ligase. The ligated DNA was purified by phenol-chloroform extraction and ethanol precipitation and was transfected into 293 cells using the calcium phosphate method. Following observation of a cytopathic effect, recombinant Ad.nNOS was purified by plaque purification on 293 cells, as described in Section 2. a control virus and was used to generate Ad.nNOS by replacing the /3-galactosidase expression cassette with one containing an nNOS cDNA (Fig. 1) . The cDNA for rat nNOS [27] was a generous gift from Dr. Solomon H. Snyder (Johns Hopkins University). This cDNA was cloned into the plasmid pGEM CMV and the 3' untranslated region of the nNOS cDNA was removed and replaced by the SV40 VP2 polyadenylation signal (PA). The resulting plasmid, pGEM CMV nNOS pA, was used to generate recombinant Ad.nNOS by direct ligation of the right 3/4 of the parent vector genome with a DNA segment from pGEM CMV nNOS pA (comprising the nNOS cDNA and SV 40 pA, the early CMV enhancer, the left terminal repeat of Ad5, and a segment of adenoviral DNA containing an engineered XbaI site, derived from the plasmid pGEM CMV). Details are provided in the legend to Fig. 1 .
Viral DNA was purified from 293 cells infected with the parent vector Ad.Pac p Gal and was restriction digested with XbaI. The 27 kb viral DNA fragment was isolated from a low melt agarose gel using /3-agarase digestion and ethanol precipitation. The plasmid pGEM CMV nNOS pA was restriction digested with XbaI and ClaI, and the 6 kb fragment was isolated and purified. The 6 kb plasmid fragment and the 27 kb viral fragment were ligated in vitro using T4 DNA ligase at room temperature for 1 h. The ligation mixture was purified using phenolchloroform extraction and ethanol precipitation, then transfected into 293 cells using the calcium phosphate method. After observation of a cytopathic effect (approximately 5-7 days), the cells were lysed by multiple freeze cell cycles and recombinant virus was isolated by plaque assay on 293 cells. Plaques expressing high levels of enzymatitally active NOS as judged by Griess assay [28] were isolated by two rounds of plaque purification [29] .
2.2. Purijcation of high titer Ad.nNOS stock Using plaque purified Ad.nNOS described above, we generated high titer stock by infecting forty 150-mm plates of confluent 293 cells, at an multiplicity of infection of 1, in DMEM/2% FBS. After observation of a cytopathic effect, cells were harvested and virus was purified on a cesium chloride gradient, using modifications of existing methods [29] . Briefly, the 293 cell pellet was lysed by Dounce homogenization, cell debris was pelleted, and the supematant was adjusted to a density of 1.1 g . ml-' by the addition of solid cesium chloride. This solution was layered onto a 1.3 g . ml-' -1.4 g . ml-' cesium chloride step gradient and ultracentrifuged for 2.5 h at room temperature. The visible band of pure virus was harvested and desalted by serial gel filtration on Sepharose CL-6B spin columns (Pharmacia, Uppsala, Sweden) in virus storage buffer (VSB; 20 mM Tris pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl,). Gel filtered virus was diluted 1: 1 with 80% fetal bovine serum (FBS)/20% glycerol and immediately frozen in aliquots. Titers of all viral stocks were determined by plaque assay on 293 cells using standard techniques [29] Louis, MO) (HUVEC). Media were from Gibco BRL (Bethesda, MD), contained 100 E.cg . ml-' penicillin and streptomycin and were supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone, Logan, UT). Human VSMC were cultured in DMEM supplemented with epidermal growth factor and fibroblast growth factor (Clonetics). During viral infection, serum concentration was reduced to 2% (293 cells) or was removed completely and replaced by 0.1% bovine serum albumin (hVSMC and HUVEC).
Infection of cultured cells with Ad.nNOS and determination of nNOS expression and activity
Cells were cultured to confluence in 6-well plates and infected for 1 h at 37°C with Ad.nNOS, using the titers indicated in the figures. Cells were cultured for an additional 24 h (in the case of 293 cells) or for 72 h (all other cell types> to allow protein expression. When the tetrahydrobiopterin precursor sepiapterin [30] (obtained from Dr. Schirks, Jonas, Switzerland) was used to increase cellular tetrahydrobiopterin levels, it was added to culture media at a concentration of 100 PM following viral infection. To determine NOS activity, cells were washed in phosphatebuffered saline (PBS), and incubated at 37°C in KrebsHenseleit buffer (NaCl 120 mM, KC1 4.7 mM, CaCl, 2.5 mM, MgSO, 1.2 mM, KH,PO, 1.2 mM, NaHCO, 25 mM, Glucose 5.5 mM, pH 7.4) containing 1 mM L-arginine and the calcium ionophore A23187 (Sigma, St. Louis, MO), at 1 PM. In some cases, the NOS inhibitor N-monomethyl-L-arginine (NMMA, Sigma) was added at 1 mM. After 6 h, the incubation buffer was assayed for nitrite concentration using the Griess assay [28] . In preliminary experiments, we measured both nitrite and nitrate production by first enzymatically reducing nitrate to nitrite using nitrate reductase. Nitrate levels were approximately 30% of nitrite levels. These proportions remained consistent between experiments, and did not vary with total nitrite/nitrate levels. We therefore chose to measure nitrite alone to determine NOS activity, since prior dilution and incubation of samples for nitrate reduction reduced the overall sensitivity and precision of the Griess assay. NOS activity was expressed as the nmol of nitrite generated per mg of cellular protein per hour. The background level of nitrite generation in buffer incubated with control cells (0.5 -1.0 nmol nitrite . (mg protein)-' . h-'> was subtracted from all wells to give the net nitrite production. The lower limit of sensitivity of the Griess assay was approximately 0.5 nmol nitrite . (mg protein)-' . h-'. In some experiments, we used physiologic agonists (acetylcholine (ACh) or bradykinin (BK)) or thapsigargin (TG) to stimulate nNOS activity in hVSMC. ln these experiments, we used a shorter incubation period (I hl and measured NO generation using a chemiluminescence method, which has a much greater sensitivity than the Griess reaction. NO was measured using a Nitrolite flow through system (Thermedics, Wobum, MA), following the reaction of NO with ozone in helium gas, as described [3 11 . Briefly, KHB was aspirated from the cells and immediately mixed, at 4°C with 2 N HCl containing glutathione (GSH) to achieve a final pH of 1.5 and a GSH concentration of 200 PM. This method effectively traps NO and nitrite as S-nitrosoglutathione (GSNO), from which NO is released by ultraviolet photolysis in the Nitrolite system. Calibration was performed using standard known concentrations of GSNO, which gave a linear response over the range 50-1000 pm01 GSNO. NOS activities in Ad.NOS-infected cells and control cells were compared using an unpaired Student's r-test. A P value less than 0.05 was considered statistically significant.
NOS protein analysis by Western immunoblotting
After incubations to measure NOS activity, cells were harvested by scraping and pelleted by centrifugation. The cell pellet was resuspended in 150 ~1 ice-cold PBS containing phenylmethyl-sulfonylfluoride (0.2 mg . ml-' ) and leupeptin (0.5 pg . ml-' ), and lysed by sonication. Cell debris was pelleted and total protein concentration in the cell lysate was determined using the Bradford assay (BioRad Laboratories, Richmond, CA). Equal samples (approximately 25 pug total protein) were separated by SDS-PAGE on 9% polyacrylamide gels and electrophoretically transferred to a nitrocellulose membrane for Western analysis. The membrane was blocked in 5% non-fat milk and incubated with primary antibody for 1 h at room temperature. For detection of nNOS, eNOS and iNOS, isoformspecific mouse monoclonal anti-NOS peptide antibodies were used at the manufacturer's specified concentration (Transduction Laboratories, Lexington, KY). Protein bands were visualized using an anti-mouse IgG horseradish peroxidase-conjugated antibody followed by chemiluminescence. To quantify relative quantities of nNOS in cell lysates, serial dilutions of equal quantities of total protein were anal!!zed by Western blotting and bands were quantified by laser densitometry (LKB Ultroscan XL). Relative protein quantity was expressed in arbitrary units. Linear regression, using the least squares method, was used to correlate enzyme activity with protein levels. Using a novel adenoviral vector system derived from in340, we constructed a recombinant adenovirus expressing nNOS. The construction is described in Fig. 1 and Section 2. Successful recombinants were selected on the basis of ionophore-stimulated nitrite production, and confirmed by analysis of viral DNA by restriction digestion. We ev.aluated the efficacy of Ad.nNOS gene transfer in 293 cells by comparing levels of nNOS protein and activity with those in a 293 cell line stably transfected with an nNOS expression plasmid. These cells, 293.NOS cells, are a well characterized source of supraphysiologic levels of nNOS and have been used to study nNOS function and regulation [27, 33] . In 293.NOS cells, immunoreactive nNOS was readily detectable (Fig. 2) . The 293.NOS cells generated high levels of nitrite after stimulation with catcium ionophore. Nitrite generation was enhanced by the presence of the BH4 precursor sepiapterin, and was inbibited by Ithe arginine analog, N-mono-methyl-L-arginine (NMMA). In mock-infected 293 cells, immunoreactive nNOS protein was not detected and nitrite production was not significantly elevated over background. This was also the case after infection with Ad.Pac j3 Gal, a marker virus encoding /3-galactosidase (data not shown).
We compared these results with nNOS protein expression and enzyme activity in 293 cells infected with Ad.nNOS. We observed high-level nNOS expression and nitrite production after Ad.nNOS infection (Fig. 2) . Cells were infected for 1 h in 1 ml low serum medium containing 2.5X 10' pfu.ml-' Ad.nNOS (multiplicity of infection 25). or mock infection with medium alone. After 24 h incubation in growth medium with or without the addition of sepiapterin (100 PM), cells were stimulated for 4 h in Krebs-Henseleit buffer (KHB) containing 1 PM calcium ionophore (A23 187), in the presence or absence of 1 mM N-mono-methyl-L-arginine (NMMA). NOS activity was determined by measurement of nitrite concentration, using the Griess reaction, and is expressed as the quantity of nitrite produced per hour per mg of protein in the total cell lysate from each dish, having subtracted the background nitrite concentration in control medium (approximately 1 nmol nitrite.(mg protein)-'. h-'1. Values represent the means of duplicate determinations (n = 2). and error bars represent standard deviations. Also shown is the statistical significance of the result compared with control cells (* P < 0.05; * * P < 0.01). The inset shows Western analysis of equal quantities of total cell lysate for nNOS expression. The arrow ('nNOS') shows the position of the nNOS protein band in a positive control sample. The experiment was repeated twice with similar results. nNOS protein and activity in 293 cells, exceeding that found in 293.NOS cells.
Human vascular smooth muscle cells
We next sought to characterize nNOS gene transfer to human vascular smooth muscle cells (hVSMC). These cells were chosen because of their relevance to vascular gene therapy. Ad.nNOS infection resulted in nitrite production which was stimulated by calcium ionophore and inhibited by NMMA (Fig. 3) . The level of NOS activity in Ad.nNOS-infected hVSMC approached 50% of that observed in 293.NOS cells. Sepiapterin more than doubled NOS activity but had no effect on levels of immunoreactive nNOS protein. Western analysis revealed expression of nNOS in Ad.nNOS infected cells, but not in cells infected with a Pgalactosidase encoding virus (Ad.Pac p Gal) or after mock infection. Adenoviral infection of hVSMC did not induce iNOS, as judged by Western analysis (data not shown). These findings were not specific for human cells; in rabbit primary VSMC, Ad.nNOS infection resulted in a maximum NOS activity of 5.5 nmol nitrite . (mg protein) -' . h-', and similar patterns of nNOS expression and activity were also observed in porcine VSMC, and in the rat A10 VSMC cell line.
To further demonstrate the presence of functional NOS, we stained hVSMC for NADPH-diaphorase activity [32] . Intense staining of the cytoplasm was seen in cells infected with Ad.n:NOS, whereas control cells showed no staining (Fig. 4) . This b o servation underscores the high levels of functional nNOS expressed in hVSMC following Ad.nNOS infection.
To investigate the relationship between nNOS protein expression and NOS activity, we evaluated the effect of infectious titer on these parameters. Both protein expres- Fig. 4 . NADPH-diaphorase staining of human vascular smooth muscle cells followingadenoviral gene transfer of nNOS. Human vascular smooth muscle cells were cultured to sub-confluence in S-well microscope-slide culture wells plates (2 X I O4 cells/well) and infected for 1 h in 0.1 ml medium containing 5 X 10' pfu 'ml-' Ad.nNOS (multiplicity of infection 250) (panels B and C), or mock infection in medium alone (panel A). After 72 h incubation in growth medium with the addition of sepiapterin (100 PM), cells were fixed and stained for NADPH-diaphorase activity, as described in Section 2. Intense purple staining shows the presence of NADPH-diaphorase activity. Original magnification: panels A and B X 33, panel C X 100). sion and activity increased progressively with increasing titer of viral infection (Fig. 5) ; this relationship was linear up to a titer of 2 X lo* pfu * ml-' (r2 = 0.95, P < 0.005).
We next investigated the ability of physiologic agonists, known to stimulate NO production in vascular cells in vivo, to activate nNOS in hVSMC following Ad.nNOS infection. This question is important since it addresses the utility of Ad.nNOS for NO generation in physiologic settings. After Ad.nNOS infection, but not after Ad.Pac /3 Gal infection or in uninfected cells, receptor-mediated NO generation was stimulated both by acetylcholine (ACh, 1 After incubation in growth medium for 3 days, with the addition of sepiapterin (100 PM), cells were stimulated for 1 h by the addition of acetylcholine (ACh, 1 PM), bradykinin (BK, 2 PM), thapsigargin (TG. 0.5 PM) or calcium ionophore (A23187, 1 PM) in Krebs-Henseleit buffer (KHB). NO and nitrite were measured in KHB using the Nitrolite chemilummescence system; NOS activity is expressed as the quantity of nitrite produced per hour per mg of protein in the total cell lysate from each dish, following subtraction of background nitrite levels. Values represent the means of duplicate determinations (n = 2), and error bars represent standard deviations. Also shown is the statistical significance of the result compared with control cells ( *P < 0.05; * * P < 0.01). The inset shows Western analysis of equal quantities of total cell lysate for nNOS or P-galactosidase ( p Gal) expression. The arrows ('nN0.S' or 'p Gal') show the positions of nNOS or 0 Gal protein bands in positive control samples.
PM) and by bradykinin (BK, 2 PM) (Fig. 6 ). Levels of NOS activity stimulated by ACh or BK were approximately 40% or 50% respectively of the maximal activity stimulated by A231 87. Receptor-independent nNOS activity could be stimulated not only by A231 87 but also by thapsigargin (TG, 0.5 PM), which stimulates a rise in intracellular Ca2+ by inhibiting intracellular Ca2+-ATPase activity [31] . Use of the chemiluminescence method for determination of A23 187-stimulated NOS activity gave very similar values to those obtained by Griess assay in separate experiments (Fig. 3) . As in previous experiments, nNOS protein expression was present equally in all cell dishes infected with Ad.nNOS, but was not seen in control cells or cells infected with Ad.Pac p Gal. Conversely, high level P-galactosidase expression was seen only in Ad.Pac p Gal infected hVSMC. These data demonstrate that nNOS expressed in hVSMC following Ad.nNOS gene transfer is regulated in a calcium-dependent manner by both receptor-dependent and receptor-independent agonists, analogous to native eNOS in endothelial cells [31] . Importantly, these findings highlight the potential utility of Ad.nNOS gene transfer for NO generation in in-vivo settings. cells/well) and infected for 1 h in 1 ml serum-free medium containing 5X 10' pfu.ml-' Ad.nNOS (multiplicity of infection 100). or mock infection with medium alone. After 72 h incubation in medium with or without the addition of sepiapterin (100 PM), cells were stimulated for 6 h in Krebs-Henseleit buffer (KHB) containing 1 PM calcium ionophore (A23187). NOS activity was determined by measurement of nitrite concentration, using the Griess reaction, and is expressed as the quantity of nitrite produced per hour per mg of protein in the total cell lysate from each dish, having subtracted the background nitrite concentration in control medium. Values represent the means of duplicate determinations (n = 2). and error bars represent standard deviations. Also shown is the statistical significance of the result compared with control cells ( *P < 0.05; * l P < 0.01). The inset shows Western analysis of equal quantities of total cell lysate for expression of eNOS and nNOS. The arrows show the position of eNOS and nNOS protein bands in positive control samples.
Huimn umbilical vein endothelial cells
In HUVEC, endogenous NOS activity (i.e., eNOS) was present that was stimulated by A23 187 and inhibited by NMMA (Fig. 7) . Infection with Ad.nNOS enhanced the total NOS activity by approximately 50%. Although sepiapterin h,ad virtually no effect on eNOS activity, the additional NOS activity generated by Ad.nNOS infection depended entirely on the presence of sepiapterin. Western blotting revealed only eNOS in uninfected HUVEC, whereas in Ad.nNOS infected HUVEC, both eNOS and nNOS were present. Induction of iNOS was not detected in either uninfected HUVEC or in HUVEC following Ad.nNOS infection (data not shown). Thus, total NOS activity in HUVEC can be significantly augmented by Ad.nNOS-mediated gene transfer, again indicating the high-level expression obtained using Ad.nNOS.
Discussion
In this report we describe for the first time the construction of a recombinant adenovirus, Ad.nNOS, for gene transfer of nitric oxide synthase, a potentially important candidate gene for cardiovascular gene therapy. We show that Ad.nNOS infects a variety of cell types, including human vascular cells, and leads to expression of functional NOS at high levels.
Eficiency of nNOS gene transfer in cultured cells
Our studies of protein expression and enzyme activity in 293 cells document the effectiveness of Ad.nNOS for gene transfer in cultured cells. 293.NOS cells express about lo-fold higher levels of functional nNOS than cerebellar tissue [27]; nevertheless, Ad.nNOS-infected 293 cells meet or exceed the supraphysiologic NOS levels observed in 293.NOS cells. Since the 293.NOS cell line is a well established high-level nNOS expression system, these findings demonstrate the utility of Ad.nNOS as a novel system for nNOS expression at even higher levels. Our adenoviral expression system also has the advantage of flexibility and versatility: we demonstrate high-level nNOS expression in a variety of cell types from different species. In addition, recombinant viruses based on Ad.nNOS could be used to express different NOS isoforms, or to express mutant NOS's for the study of NOS structure-function relationships or NOS regulation.
We also studied Ad.nNOS gene transfer in hVSMC and HUVEC, :since vascular cells are more directly relevant to human gene therapy applications [4, 9, 34] . Adenoviruses have been widely used to infect these cell types with both marker and functional genes [5-l 11 . Ad.nNOS gene transfer again proved highly efficient. In hVSMC, Ad.nNOS infection results in nitrite levels about one-third of that observed in 293.NOS cells or in uninfected HUVEC. NOS activity was readily quantified using the simple but insen-sitive Griess assay, without recourse to more complex isotopic methods [35] . We also used a more sensitive chemiluminescence method to determine NOS activity in hVSMC after short stimulation periods with the physiologic agonists acetylcholine (ACh) and bradykinin (BK). Using this alternative method, the values of A23187-stimulated NOS activity were very similar to those obtained with the Griess assay in independent experiments, demonstrating the consistency and reproducibility of our NOS activity measurements. Our demonstration of nNOS activation in hVSMC by ACh or BK is an important result. First, it shows that nNOS, a heterologous protein expressed in hVSMC, is nevertheless subject to physiologic regulation by intracellular Ca*+ through receptor-mediated pathways, in a manner analogous to eNOS activation in endothelial cells [36] . Second, since VSMC are the targets of gene transfer in arteries denuded of endothelium [37, 38] , this observation suggests that Ad.nNOS gene transfer may be effective in restoring physiologic NO production in an injured vessel. Native HUVEC contain high levels of eNOS [31] . Nevertheless, Ad.nNOS infection of HUVEC substantially augments total NOS activity, further highlighting the ability of adenoviral gene transfer to produce biologically significant NOS activity. Taken together, these observations demonstrate that Ad.nNOS generates highlevel, physiologically-regulated NOS activity in human vascular cells, potentially important targets for NOS gene transfer.
In each figure, we report data from representative experiments done in duplicate. All experiments were repeated two to three times, with virtually identical results. However, we did observe modest (less than two-fold) inter-experimental variations in total nitrite production that we believe were primarily attributable to changes in viral preparations. In order to combine results from separate experiments, it would have been necessary to normalize data between experiments. Since we felt this would have obscured the data's quantitative aspects, we elected not to pursue this course. It is important to note that uninfected cells do not express any nNOS, whereas Ad.nNOS-infected cells express high levels of nNOS. The differences between control and Ad.nNOS infected cells are qualitatively different, both in terms of nNOS protein expression and NOS activity.
Modulation of NOS activity by sepiapterin
Although cytokine stimulation induces iNOS protein expression in VSMC, tetrahydrobiopterin (BH4) is an absolute requirement for NOS activity [30, 39] . BH4 is undetectable in unstimulated cultured VSMC, but cytokine stimulation also rapidly upregulates GTE-cyclohydrolase (GTE-CH; EC 3.5.4.16), the rate-limiting enzyme for de novo BH4 synthesis. Our data from Ad.nNOS-infected hVSMC are entirely consistent with these observations: enhancement of NOS activity above baseline requires supplementation with sepiapterin (a BH4 precursor which is converted to BH4 by the GTE-CH-independent pterin salvage pathway [30] ). The observed sepiapterin requirement suggests that adenoviral gene transfer does not upregulate GTE-CH. These observations may have important implications for NOS gene therapy: in vivo enhancement of NO production may require an increase in BH4 levels. Co-infection with an adenovirus expressing GTE-CH would likely enhance BH4 synthesis, providing a potential solution to this problem. However, BH4 supplementation was not required for eNOS activity following in vivo gene transfer of eNOS by plasmid transfection, [24] , suggesting that BH4 availability may be less limiting in vivo than in cultured cells.
Potential utility of nNOS gene transfer
Adenoviral gene transfer of NOS provides a new approach to investigating intracellular NOS regulation, and the cellular mechanisms underlying the pathogenesis of various diseases, such as neuronal degeneration, myocardial injury and atherosclerosis. In the cardiovascular system, NOS gene transfer represents a potentially important therapeutic strategy. Endothelial dysfunction is an early and consistent marker of vascular injury, and loss of nitric oxide production may facilitate atherosclerotic progression in a number of ways [40, 41] . Accordingly, restoration of nitric oxide production by gene therapy may normalize vasomotor function, and may limit atherosclerotic progression. Such a beneficial effect of vascular NOS gene transfer was recently demonstrated in a denuded rat carotid artery model, using modified plasmid-liposome complexes [24] . An adenoviral approach offers potential advantages over liposome-mediated gene transfer, although the relative merits of each remains the focus of intense investigation [31. Although eNOS is the only NOS isoform found in the normal vessel wall, it does not necessarily follow that eNOS will be superior to other NOS isoforms for vascular gene therapy. iNOS has the theoretical advantage of sustained high-level activity independent of agonist stimulation [ 12, 131, but its effects may prove cytotoxic rather than beneficial [ 161. In contrast, eNOS and nNOS are functionally similar; both are calmodulin-regulated, and produce NO transiently in response to agonist stimulation. Although eNOS is myristoylated and predominantly membrane associated, the functional similarities make it likely that gene-transferred nNOS could act as a surrogate for eNOS in the vascular wall. This is clearly illustrated by our demonstration that nNOS gene transfer significantly augments total NOS activity in HUVEC, a cell type that normally expresses only eNOS. Whereas eNOS gene transfer is one approach to restoring deficient vascular NO production, we hypothesized that the neuronal isoform of NOS would behave in a physiologic, calcium-dependent manner in a variety of other target cells (including vascular smooth muscle cells). Finally, a practical advantage of using nNOS for experimental vascular gene transfer is that NOS protein expression resulting from gene-transfer can be specifically distinguished from native eNOS by isoform-specific Western analysis, as we showed in HUVEC.
In summary, we have generated a recombinant adenovirus, Ad.nNOS, encoding an NOS isoform. We demonstrate that Ad.nNOS generates high levels of nNOS protein in vascular cells and that the expressed NOS is functional in response to both receptor-independent stimulation and to receptor-mediated agonists. Ad.nNOS provides a novel tool for high-level transient expression of NOS in cultured vascular cells and may have applications for vascular gene therapy.
